Applications of a human tumour clonogenic cell culture system in gynaecological oncology: review and personal experience.
Current and future clinical applications of the Human Tumour Clonogenic Cell Culture (HTC3) system are presented. Advanced gynaecological cancers, especially ovarian, endometrial and cervical carcinomas, require extensive systemic chemotherapy. The HTC3 system seems to be an adequate instrument for individualized chemosensitivity testing in order to choose proper cytostatic treatments; that is, maximum tumour cell kill with minimal side-effects. Furthermore, this system helps in assessing the response after treatment by detection of remaining clonogenic, and thus viable, tumour cells. Other clinical applications of the system include grading of the tumour and recognition of the histologic type. Thus the HTC3 provides a potential tool in diagnosis, treatment and follow-up of gynaecologic malignancies.
D000970:Antineoplastic Agents / Q000008:administration & dosage; D003114:Colony-Forming Units Assay; D004353:Drug Evaluation, Preclinical; D004351:Drug Resistance; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D014410:Tumor Stem Cell Assay; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents